Skip to content
Biodatica
Start free

Genmab

Boston, Massachusetts

OncologybispecificPhase IIIListed · GMAB

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

2d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Aug 1, 2026

    Solid Tumours · NOT_YET_RECRUITING · sponsor: Genmab · A Phase 1 Trial of GEN1119 in Participants With Solid Tumors

    ClinicalTrials.gov · NCT07695831 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jun 1, 2026

    Platinum-resistant Ovarian Cancer · NOT_YET_RECRUITING · sponsor: Genmab · An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

    ClinicalTrials.gov · NCT07604766 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Apr 3, 2026

    Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC · RECRUITING · sponsor: Genmab · Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    ClinicalTrials.gov · NCT07225270 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jul 25, 2025

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV) · TERMINATED · sponsor: Genmab · Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

    ClinicalTrials.gov · NCT06984328 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Feb 7, 2025

    Platinum-resistant Ovarian Cancer · ACTIVE_NOT_RECRUITING · sponsor: Genmab · Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

    ClinicalTrials.gov · NCT06619236 (opens the source filing in a new tab)

  6. Trial

    PHASE1/PHASE2 registered

    Jan 29, 2025

    Malignant Solid Tumor · TERMINATED · sponsor: Genmab · A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors

    ClinicalTrials.gov · NCT06771921 (opens the source filing in a new tab)

  7. Trial

    PHASE1/PHASE2 registered

    Nov 13, 2024

    Advanced Solid Tumor · TERMINATED · sponsor: Genmab · A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

    ClinicalTrials.gov · NCT06685068 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    May 14, 2024

    Malignant Solid Tumor · TERMINATED · sponsor: Genmab · Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

    ClinicalTrials.gov · NCT06391775 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources